As of 2026-02-28, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -2.30. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 110.56 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -48.15 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.7x - 10.1x | 8.1x |
| Forward P/E multiples | 6.8x - 10.5x | 8.5x |
| Fair Price | (3.20) - (4.90) | (3.98) |
| Upside | -318.5% - -434.9% | -371.8% |
| Date | EV/EBITDA |
| 2026-02-27 | -2.30 |
| 2026-02-26 | -2.37 |
| 2026-02-25 | -2.34 |
| 2026-02-24 | -2.35 |
| 2026-02-23 | -2.18 |
| 2026-02-20 | -2.18 |
| 2026-02-19 | -2.26 |
| 2026-02-18 | -2.27 |
| 2026-02-17 | -2.25 |
| 2026-02-16 | -2.26 |
| 2026-02-13 | -2.30 |
| 2026-02-12 | -2.20 |
| 2026-02-11 | -2.17 |
| 2026-02-10 | -2.22 |
| 2026-02-09 | -2.18 |
| 2026-02-06 | -2.23 |
| 2026-02-05 | -2.35 |
| 2026-02-04 | -2.41 |
| 2026-02-03 | -2.40 |
| 2026-02-02 | -2.46 |
| 2026-01-30 | -2.46 |
| 2026-01-29 | -2.47 |
| 2026-01-28 | -2.39 |
| 2026-01-27 | -2.34 |
| 2026-01-26 | -2.36 |
| 2026-01-23 | -2.43 |
| 2026-01-22 | -2.48 |
| 2026-01-21 | -2.33 |
| 2026-01-20 | -2.40 |
| 2026-01-19 | -2.37 |
| 2026-01-16 | -2.38 |
| 2026-01-15 | -2.37 |
| 2026-01-14 | -2.39 |
| 2026-01-13 | -2.40 |
| 2026-01-12 | -2.47 |
| 2026-01-09 | -2.41 |
| 2026-01-08 | -2.43 |
| 2026-01-07 | -2.48 |
| 2026-01-06 | -2.47 |
| 2026-01-05 | -2.49 |
| 2026-01-02 | -2.59 |
| 2025-12-31 | -2.56 |
| 2025-12-30 | -2.58 |
| 2025-12-29 | -2.45 |
| 2025-12-24 | -2.46 |
| 2025-12-23 | -2.41 |
| 2025-12-22 | -2.49 |
| 2025-12-19 | -2.43 |
| 2025-12-18 | -2.47 |
| 2025-12-17 | -2.50 |